TREM1 Blockade Ameliorates Lipopolysaccharide-Induced Acute Intestinal Dysfunction through Inhibiting Intestinal Apoptosis and Inflammation Response

Objective The lipopolysaccharide- (LPS-) induced acute intestinal dysfunction model has been widely applied in recent years. Here, our aim was to investigate the effect of triggering receptor expressed on myeloid cells-1 (TREM1) inhibitor in LPS-induced acute intestinal dysfunction. Methods Male rats were randomly assigned into normal (saline injection), model (LPS and saline injection), and LP17 (LPS and LP17 (a synthetic TREM1 inhibitor) injection) groups. The levels of intestinal TREM1 expression were evaluated by immunohistochemistry and western blot. Intestinal permeability and apoptosis were separately assessed by the lactulose/mannitol (L/M) ratio and TUNEL assay. The levels of soluble TREM1 (sTREM1), TNF-α, IL-6, and IL-1β were measured in the plasma and intestinal tissues by ELISA. The expression levels of NF-κB, high-mobility group box 1 (HMGB1), and toll-like receptor 4 (TLR-4) were measured with RT-qPCR and western blot. After transfection with si-TREM1 in LPS-induced intestinal epithelium-6 (IEC-6) cells, p-p65 and p-IκBα levels were detected by western blot. Results LP17-mediated TREM1 inhibition alleviated the intestine tissue damage in rats with LPS-induced acute intestinal dysfunction. LP17 attenuated the LPS-induced increase in sTREM1, TNF-α, IL-6, and IL-1β levels in the plasma and intestinal tissues. Furthermore, intestine permeability and epithelial cell apoptosis were ameliorated by LP17. LP17 attenuated the LPS-induced increase in the expression of TREM1, HMGB1, TLR-4, and NF-κB in the intestine tissues. In vitro, TREM1 knockdown inactivated the NF-κB signaling in LPS-induced IEC-6 cells. Conclusion LP17 could ameliorate LPS-induced acute intestinal dysfunction, which was associated with inhibition of intestinal apoptosis and inflammation response.


Introduction
Intestinal inflammation is the host's invasion defense response through microbial toxins (such as lipopolysaccharide (LPS)) or pathogens (such as Escherichia coli) [1], which is a key risk factor for highly fatal diseases like colorectal cancer [2]. Immunity imbalance and mucosal barrier destruction are the main mechanisms of intestinal inflammation [3].
Inflammation may thin the mucosal layer, reduce the lumen coverage and the adhesion, and destroy the integrity of the intestine by increasing the apoptosis and permeability of epithelial cells and inhibiting cell proliferation, inducing the loss of barrier function, and ultimately leading to acute intestinal dysfunction [4][5][6]. Furthermore, acute intestinal dysfunction triggers the spread of metabolites, endotoxins, and bacteria, an effect caused by enterogenous bacteremia, thereby exacerbating sepsis and multiple organ dysfunction syndrome (MODS) [4][5][6]. Previous studies on biomarkers of intestinal failure have demonstrated that the disease severity and intensive care unit mortality have both been linked to elevated expression of intestinal fatty acid-binding protein (I-FABP, a biomarker of enterocyte damage), decreased expression of citrulline (a biomarker of enterocyte mass and damage), and increased intestinal permeability [7,8]. Although our understanding on the pathophysiology of acute intestinal dysfunction has been greatly improved [9], the treatment of acute intestinal dysfunction is restricted to proton-pump inhibitors, antibiotics, and parenteral nutrition [10]. So far, no targeted therapeutics for acute intestinal dysfunction have been approved for clinical use [9].
Triggering receptor expressed on myeloid cells-1 (TREM1) belongs to a family of innate immune receptors, which is mainly expressed on murine and human granulocytes and monocytes/macrophages [11]. TREM1 can synergize with various toll-like receptors (TLRs) and trigger nuclear factor-(NF-) κB signaling to induce the expression of proinflammatory cytokines, such as tumor necrosis factor-(TNF-) α, interleukin-(IL-) 6, and IL-1β, thereby amplifying inflammatory response [12][13][14][15]. Furthermore, soluble TREM1 (sTREM1) has been proposed as a diagnostic and prognostic biomarker for patients with septic shock [16]. It has been shown that TREM1 is a promising diagnostic biomarker and therapeutic target for sepsis [17]. However, TREM1 expression is absent in myeloid cells of the normal intestine, which is a key mechanism for the prevention of intestinal inflammation and excessive tissue damage [18].
As in previous studies, it has been confirmed that TREM1 participates in inflammatory bowel diseases [19]. It promotes the progression of inflammatory bowel disease by enhancing proinflammatory response [20]. Blocking TREM1 expression can protect mice from intestinal ischemia-reperfusion injury [21]. Furthermore, TREM1 induces intestinal barrier dysfunction associated with pancreatitis [22]. Thus, TREM1 may play a key role in acute intestinal dysfunction. LPS is the main component of the cell wall of Gram-negative bacteria, which plays an important role in mediating intestinal inflammatory response [23]. Recent studies have shown that physiologically relevant LPS concentrations (0 to 1 ng/ml) can increase intestinal epithelial TJ permeability [24]. The LPS injury model has been widely applied in studying the intestinal TJ barrier. It has been reported that LP17, a synthetic TREM1 inhibitor, has a protective effect on LPS-induced lung injury [25] and can be used to treat mice with LPS-induced septic shock [26]. However, it remains unclear whether LP17 could protect against LPS-induced acute intestinal dysfunction and the related molecular mechanisms.
The LPS-induced acute intestinal dysfunction model has been widely used in recent years. For example, based on the LPS-induced intestinal injury model, it has been found that Rhein could ameliorate inflammatory and oxidative responses via modulating Nrf2 and MAPKs [27]. Furthermore, proanthocyanidins ameliorate inflammatory response and intestinal permeability in an LPS-induced intestinal injury rat model [28]. Thus, it is rational to use the intestinal injury model induced with LPS. In this study, we hypothesized that TREM1 inhibitor LP17 could ameliorate intestinal apoptosis and inflammatory response in LPS-induced acute intestinal dysfunction rats. Furthermore, we analyzed its relevant molecular mechanisms.

Animals and LPS-Induced Acute Intestinal Dysfunction
Model. Sixty adult male Sprague Dawley (SD) rats (weighing 260-280 g; eight weeks old) were purchased from the specific pathogen free (SPF) Laboratory of the Animal Laboratory Center at the Key Laboratory on Technology for Parasitic Disease Prevention and Control, Ministry of Health (Wuxi City, China). All rats were maintained at 22 ± 1°C room temperature with a 12/12 h light/dark cycle and had free access to food and water. These rats were randomly assigned into three groups: normal group, LPSinduced acute intestinal dysfunction group, and LP17 group. The LPS-induced acute intestinal dysfunction model was established by intraperitoneal injection of 4.5 mg/kg LPS, as previously reported [29]. LP17 peptide (LQVTDSGLYRCVIYHPP) was synthesized by Shanghai Science Peptide Biological Technology Co., Ltd. (Shanghai, China). Its molecular weight was 2074.41, and purity was 98.22% that was verified by mass spectrometry and highperformance liquid chromatography (HPLC). LP17 synthetic peptide (3.5 mg/kg body weight [11]; Sigma, St. Louis, MO, USA) was administered to the LPS-induced acute intestinal dysfunction rats in the LP17 group through the vena caudalis at the time of LPS injection, while the rats in the normal and model groups were injected with an equal amount of saline. All rats were anesthetized by intraperitoneal injection of sodium pentobarbital (200 mg/kg body weight) and then euthanized with CO 2 inhalation at 108 h after LPS administration. This animal experiment was approved by the Animal Care and Use Committee at Wuxi Hospital of Traditional Chinese Medicine (Wuxi, City, China). Our animal experimental procedures were conducted following the Guide for the Care and Use of Laboratory Animals.

Specimen
Collection. 72 h after LPS administration, all rats were administered by 2 ml isomolar solution containing 100 mg lactulose and 50 mg mannitol by intragastric administration, as previously described [30]. Urine samples were collected from each animal in a metabolic cage for over 24 h. Subsequently, 2.5 ml urine was stored in a smaller bottle containing 0.6 mg thimerosal to avoid bacterial growth. Blood samples were obtained from the orbital venous plexus 12 h later. After centrifuging the blood samples at 2000 × g for 10 min, the serum was stored at -80°C. After euthanizing the rats, small intestine tissues including intestinal feces were collected and frozen rapidly in liquid nitrogen and stored at −80°C for immunohistochemistry and pathological examination.

2
BioMed Research International 2.3. Enzyme-Linked Immunosorbent Assay (ELISA). ELISA was used to determine the levels of sTREM1, TNF-α, IL-6, I-FABP, and citrulline [31] in the serum and cell supernatant using commercial kits (all from Shanghai Hufeng Chemical Co., Ltd., Shanghai, China) according to the manufacturer's protocols. The absorbance (optical density, OD) of each well was measured at a wavelength of 450 nm with a BioTek ELx800 microplate reader (Winooski, VT, USA).

HPLC Analysis of Intestinal Permeability.
A lactulose/mannitol (L/M) ratio > 0:03 was used to define an increase in intestinal permeability. A L/M ratio > 0:10 was defined as a marked increase in intestinal permeability [30]. The urine samples were examined by HPLC using a Dionex Carbon-Pac PA1 ion exchange column at 30°C and equipped with a pulsed amperometric detector integrator using an Au main electrode and an AgCl reference electrode, and a water and NaOH gradient mobile phase [32]. A 1525 HPLC device (Waters, Milford, MA, USA) equipped with a 2489 UV detector (5 μm, 4:6 × 250 mm, XBridge C18 column) was used for the metabolite analyses, and the device was operated by an Empower2 chromatography workstation.

Hematoxylin-Eosin (H&E) Staining of Small Intestine
Tissues. The small intestine tissues were fixed in 10% formalin, dehydrated, paraffin-embedded, and sectioned. H&E staining of the sections was performed as previously described [33]. Under microscopy, the pathological changes of villi, intestinal layers, and epithelial cells were assessed by experienced pathologists. The DX45 software (DP2-BSW image analysis system, Olympus, Tokyo, Japan) was used to analyze the length of the villi and the mucosal thickness. Blinded procedures were ensured for the examiners by performing intergroup analysis.
2.6. Pathological Examination with Chiu Score. The six-point Chiu score was used to assess the intestinal mucosal damage based on a scale ranging from 0 to 5, with the pathological degree spanning from mild to severe [34]. The scoring system was defined as follows: 0, the normal villi of the small intestinal mucosa with no noticeable lesions; 1, the occurrence of Gruenhagen's space under the intestinal mucosa in the middle axis of villi, which was often accompanied by capillary congestion; 2, the elevation of intestinal mucosa epithelium from the lamina propria and the expansion of the upper and subcutaneous space of the intestine; 3, the elevation of large intestinal mucosa epithelium with the villi falling to both sides and villi top missing; 4, the shedding of villi and lamina propria, and the expansion of exposed capillaries, in which the cell composition of the lamina propria was increased; 5, the degeneration or digestion of the lamina propria, and bleeding or ulcer formation.

2.7.
Immunohistochemistry. Paraffin-embedded tissues were cryosectioned into 4 μm thickness, which were mounted on microscope slides with a charged surface. The UltraVision polymer detection method was used to determine the protein expression as previously described [35][36][37]. All the procedures for immunohistochemistry were based on the protocol of the commercial kit (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China). The sections were baked under 65°C for 10 min and then boiled in a citrate buffer (pH = 6) for 30 min. Immunoblocking of nonspecific background was applied to the sections by incubating the sections in a hydrogen peroxide block for 10 min at room temperature. The sections were incubated with rabbit polyclonal antibodies (1 : 500; Beijing Biosynthesis Biotechnology Co., Ltd.) at room temperature for 2 h and goat anti-rabbit IgG (1 : 5000; Beijing Biosynthesis Biotechnology Co., Ltd.) for 30 min at room temperature. After washing with running tap water, the sections were treated with DAB brown solution (1 : 20) for 1 min and washed with running tap water for 2 min. After immunostaining, the slides were mounted and digitized with a ScanScope CS2 digital pathological scanning system (Leica Biosystems, USA). The semiquantitative analysis was presented via scoring the percentage of positive cells and staining intensity. The number of positive cells was as follows: <5% was 0 points, 5%-25% was 1 point, 26%-50% was 2 points, 51%-75% was 3 points, and 76%-100% was 4 points. Positive cell staining intensity scores were as follows: 0 for colorless, 1 for light yellow, 2 for brown, and 3 for tan. The product of the number of positive cells and the positive cell staining intensity was calculated, as follows: 0 for negative, 1-4 for weakly positive, 5-8 for positive, and 9-12 for strong positive.

Terminal Deoxynucleotidyl Transferase dUTP Nick-End
Labeling (TUNEL) Staining. Apoptotic cells in the intestinal epithelium were detected by the TUNEL assay using the DeadEndTM Fluorometric TUNEL System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Briefly, after deparaffinization with proteinase K digestion and incubation with 3% H 2 O 2 blocking solution, the sections were titrated with 0.55 μl/cm 2 TdT enzyme and incubated at room temperature for 1 h. Then, the stopping solution was added to the sections, which were subsequently washed with phosphate-buffered saline (PBS) solution 4 times, 2 min for each wash. After titrated with DAB coloration solution, the sections were counterstained with 0.5% Brilliant Green and mounted with glycerol buffer. Three fields of view were randomly selected under a high-power field (×200). The number of positive cells was calculated in each field.

BioMed Research International
At 48 h after transfection, the transfection efficiency was evaluated by RT-qPCR.
2.12. Statistical Analysis. All analyses were performed using the GraphPad Prism software. Data are expressed as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used for multiple comparisons, followed by Tukey's test. Statistical significance was considered when p < 0:05.

Results
3.1. TREM1 Inhibitor LP17 Attenuates the Injury of the Small Intestine Tissues in Rats with LPS-Induced Acute Intestinal Dysfunction. To investigate the potentially protective role of LP17 on acute intestinal dysfunction, we firstly established a 4.5 mg/kg LPS-induced acute intestinal dysfunction rat model. After three days, the mortality of the control, model, and LP17 groups was 0, 30%, and 15%, respectively. Therefore, the number of remaining rats was 20 in the normal group, 14 in the model group, and 17 in the LP17 group, indicating that LP17 could decrease LPS-induced mortality. H&E staining was presented to examine the degree of injury in small intestine tissues from the three groups. As shown in Figure 1(a), the small intestine tissues in the model group displayed mild capillary congestion and denuded villi. Furthermore, they had crypts with exposed lamina propria, dilated and exposed capillaries with evidence of hemorrhage and ulceration, and increased cellularity of the lamina propria. Compared with the model group, LP17 treatment significantly ameliorated LPS-induced intestine injury. In the LP17 group, there was the extended subepithelial space with the epithelial layer lifting up in sheets, the presence of a few denuded villi, crypts with exposed lamina propria, and dilated and exposed capillaries with signs of hemorrhage and increased cellularity of the lamina propria (Figure 1(a)). Moreover, the Chiu score in the LP17 group was significantly lower than that in the model group (Figure 1(b)). Furthermore, compared with the control group, the model group had significantly reduced length of intestinal villi (Figure 1(c)) and thickness of intestinal mucosa (Figure 1(d)). However, LP17 treatment markedly and partially reversed the above changes in LPS-induced acute intestinal dysfunction rats. Since LP17 is a specific inhibitor of TREM1, we set out to determine whether the expression of TREM1 in small intestinal tissues was affected by LPS injection and LP17 administration by immunohistochemistry staining and western blot assays. As expected, the immunohistochemistry staining results demonstrated that the model group had evidently higher expressions of TREM1 than the normal group, while the LP17 group significantly attenuated the increase of TREM1 expression caused by LPS treatment (Figures 1(e) and 1(f)). Furthermore, we found that TREM1 was mainly expressed in the myeloid cells of intestinal tissues. Consistently, the similar results of TREM1 expression in small intestine tissues of rats were also observed by western blot assays (Figures 1(g) and 1(h)). Taken together, these results indicated that TREM1 inhibitor

LP17 Ameliorates Apoptosis of Intestinal Epithelium Cells and Intestinal Mucosal Permeability in LPS-Induced Acute
Intestinal Dysfunction Rats. The mucosa of the small intestine is lined by a single-layer epithelium. We next conducted the TUNEL assay to observe whether LPS injection and LP17 administration affected apoptosis of intestinal epithelium tissues. Compared with the normal group, the model group had a significantly higher number of apoptotic cells in the intestinal epithelium (Figures 2(a) and 2(b)). However, administration of LP17 remarkably reduced the number of apoptotic cells induced by LPS (Figures 2(a) and 2(b)). Elevated I-FABP and decreased citrulline levels are the indicators of enterocyte mass damage [11,12]. As shown in Figure 2(c), the expression of I-FABP in the model group was signifi-cantly higher than that in the control group. In addition, the model group showed a decreased level of citrulline in comparison to the control group (Figure 2(d)). However, LP17 administration caused a significant decrease in the I-FABP level (Figure 2(c)) and a remarkable increase in the citrulline level (Figure 2(d)) in LPS-induced rats. The tight junctions between cells are destroyed by the apoptosis of epithelial cells, thereby increasing the intestinal permeability [37]. We found that the intestinal permeability in LPSinduced rats was notably higher than in controls, as assessed by the L/M ratio (Figure 2(e)). LP17 administration resulted in a clear attenuation in the mucosal permeability damage compared with the model group (Figure 2(e)). Collectively, our results suggested that LP17 could markedly ameliorate the apoptosis of the small intestine tissues in LPS-induced acute intestinal dysfunction rats and preserve the intestinal mucosal permeability.  One-way analysis of variance (ANOVA) was used for multiple comparisons, followed by Tukey's test. * * * * p < 0:0001.

6
BioMed Research International

LP17 Reduces Intestinal and Systemic Inflammatory
Response and Activation of the NF-κB Signaling in LPS-Induced Acute Intestinal Dysfunction Rats. We further investigated whether modulation of the TREM1 pathway influenced the systemic inflammatory response in the LPSinduced acute intestinal dysfunction rats. Compared with the normal group, the model group had significantly increased plasma concentrations of sTREM1 (Figure 3(a)), TNF-α (Figure 3(b)), IL-6 ( Figure 3(c)), and IL-1β (Figure 3(d)). However, LP17 administration distinctly reduced the levels of these inflammatory cytokines in plasma of LPS-induced acute intestinal dysfunction rats (Figures 3(a)-3(d)). These inflammatory cytokines were also measured in the intestine tissues. The results showed that sTREM1 (Figure 3(e)), TNF-   (Figure 3(f)), IL-6 ( Figure 3(g)), and IL-1β (Figure 3(h)) levels were significantly increased in the intestine tissues of the model group in comparison to the normal group. After treatment with LP17, their levels were markedly reduced in the intestine tissues of the LPS-induced acute intestinal dysfunction rats (Figures 3(e)-3(h)). Moreover, we determined the mRNA expression levels of NF-κB, HMGB1, and TLR-4 in the small intestine mucosa tissues by RT-qPCR. Our results showed that there were significantly higher expression levels of NF-κB (Figure 3(i)), HMGB1 (Figure 3(j)), and TLR-4 ( Figure 3(k)) in the model group than the control group. LP17 administration distinctly decreased their mRNA expression levels in the model group (Figures 3(i)-3(k)). Western blot was also presented to detect their expression at the protein levels ( Figure 3(l)). Consistent with our RT-qPCR results, the expression levels of NF-κB (Figure 3(m)), HMGB1 (Figure 3(n)), and TLR-4 (Figure 3(o)) proteins were signifi-cantly increased in the model group compared to the control group. Under the administration of LP17, their expression levels were distinctly reduced in the small intestine mucosa tissues of LPS-induced acute intestinal dysfunction rats (Figures 3(m)-3(o)).

Knockdown of TREM1 Suppresses Inflammatory
Response and NF-κB Signaling Activation in LPS-Induced Intestinal Epithelium Cells. To substantiate the role of TREM1 in regulating inflammatory response during LPSinduced acute intestinal dysfunction, we silenced TREM1 in LPS-stimulated rat intestinal epithelium cell line IEC6. Our western blot results confirmed that TREM1 was successfully silenced in LPS-induced IEC6 cells (Figures 4(a) and 4(b)). Furthermore, we assessed the effects of TREM1 knockdown on NF-κB signaling. The results showed that compared with the negative siRNA oligo-transfected group, the knockdown One-way analysis of variance (ANOVA) was used for multiple comparisons, followed by Tukey's test. ns: no statistical significance; * * p < 0:01; * * * * p < 0:0001.

Discussion
In this study, we observed the protective effects of TREM1 inhibitor LP17 against LPS-induced acute intestinal dysfunction, which was associated with inhibition of apoptosis of intestinal epithelium cells and intestinal and systemic inflammatory responses. Mechanically, LP17 could inactivate the NF-κB signaling in LPS-induced intestinal tissues and cells.
In the current study, we constructed an LPS-induced acute intestinal dysfunction rat model. The citrulline levels in the model group were notably lower than those in the normal group, confirming that the model was successfully established. TREM1 has a major function of triggering the inflammatory response [15,22,32]. It can induce cytokine production through binding with its adaptor molecule, TYRO protein tyrosine kinase-binding protein (TYROBP) [14,15,39]. In addition, TREM1 can synergize with various TLRs, causing amplification of the inflammatory response [12,14,15,22,39,40]. Herein, we found that the expression of TREM1 was significantly elevated in LPS-induced small intestine tissues. As in previous studies, mRNA expression levels of TREM1 were negatively correlated with plasma citrulline levels [25]. Moreover, sTREM1 was distinctly upregulated in the serum of the model group in comparison to the normal group, indicating that TREM1 could be involved in the occurrence and development of LPS-induced acute intestinal dysfunction. It has been reported that the survival of LPS-induced septic shock mice can be prolonged by blocking TREM1 [26]. Wang et al. revealed that TREM1 blockade could protect animals from death caused by Pseudomonas aeruginosa-induced sepsis [39]. In this study, our results demonstrated that LP17 could markedly decrease the mortality in mice with LPS-induced acute intestinal dysfunction. Furthermore, we investigated the effects of LP17 on intestinal permeability, intestinal damage, and inflammatory response in LPS-induced rat models. Overall, model rats exhibited increased intestinal permeability and systemic and intestinal inflammation, which were ameliorated by administration of TREM1 inhibitor LP17. Also, LP17 treatment reduced the expression levels of I-FABP and increased the citrulline levels in rats with LPS-induced acute intestinal dysfunction. Partially consistent with a previous study, intestinal mucosa barrier damage in pancreatitis-associated inflammatory bowel disease models could be ameliorated by TREM1 blockade LP17 treatment [22]. These findings implied that LP17 treatment improved the intestinal barrier function and intestinal mucosa damage induced by LPS.
It has been reported that TREM1 is upregulated in neutrophils both from sepsis patients and LPS-induced septic shock mice [41]. Activation of TREM1 together with stimulation by TLR ligands such as LPS causes increased TNF-α production [42]. The activation of TLRs is closely related to TREM1 activation, and both of them act synergistically to increase inflammation [43]. Furthermore, multiple ligands, such as HMGB1 and HSP70, can activate TREM1 [44,45]. MGB1 released from macrophages can serve as a sepsis biomarker [46]. HMGB1 is a ligand of TREM1 and TLRs [47]. Previous studies have implied that increased HMGB1 levels activate TREM1 and TLR downstream signaling, leading to an increase in the secretion of inflammatory cytokines, such as IL-6, TNF-α, and IL-1β [15]. Therefore, inhibition of TREM1 can improve the inflammatory state in sepsis. To further explore the underlying molecular mechanism of LP17 on treating LPS-induced acute intestinal dysfunction, we evaluated the mRNA and protein levels of HMGB1, TLR-4, and NF-κB in small intestine tissues. The results demonstrated that LP17 distinctly reduced their expression in LPS-induced small intestine tissues. In agreement with previous studies, LP17 inhibited the LPS-stimulated increase in the levels of sTREM1, TNF-α, IL-6, and IL-1β in plasma and intestinal samples, indicating the suppression of intestinal and systemic inflammatory responses. Moreover, our results suggested that TREM1 knockdown protected against LPS-induced acute intestinal dysfunction in vitro.
Our study revealed that TREM1 could become a potential therapeutic target in LPS-induced acute intestinal dysfunction. However, undoubtedly, since the LPS-induced model may not fully represent the various types of acute intestinal dysfunction encountered in most clinical settings, and we only focused on one time point of LPS-treated intestinal injury in rats, more preclinical work should be required to consolidate the clinical application concerning TREM1 target therapy for acute intestinal dysfunction.

Conclusion
Taken together, our findings revealed that TREM1 inhibitor LP17 ameliorated LPS-induced acute intestinal dysfunction, which could be related to the inhibition of the TREM1-HMGB1-TLR-4-NF-κB signal transduction pathway as well as the downstream production of proinflammatory cytokines. These findings demonstrated that TREM1 inhibition protected rat intestinal tissues from hyperinflammatory injury in response to endotoxin. In addition, these results also indicated that TREM1 can be used as an effective therapeutic target in LPS-induced acute intestinal dysfunction. Our study could shed a new light on the development of orally bioavailable formulation of LP17 in treating patients with acute intestinal dysfunction. Intestinal epithelium-6 TNF: Tumor necrosis factor IL: Interleukin ELISA: Enzyme-linked immunosorbent assay H&E: Hematoxylin-eosin RT-qPCR: Reverse transcription and quantitative PCR.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure
The funding organizations only supported funds and did not review or supply any other inputs. The authors declare that they have no financial relationship with the organization that sponsored the research, and the funding body was not involved in study design, data collection, analysis, and writing of the study.

Conflicts of Interest
The authors declare no conflicts of interest.